



Docket No.: 58069-CON (47126)
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Gregor Cevc

Application No.: 09/887,493

Confirmation No.: 7718

Filed: June 22, 2001

Art Unit: 1655

For: IMPROVED FORMULATION FOR
TOPICAL NON-INVASIVE APPLICATION
IN VIVO

Examiner: S. D. Coe

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement, pursuant to 37 CFR 1.114(c), accompanies the Request for Continued Examination (37 CFR 1.114) submitted herewith.

An English language translation for non-English language references BA, BE-BG, CA, CN-CO, CQ-CT is enclosed.

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S.

Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 58069CON(47126). A duplicate copy of this paper is enclosed.

Dated: April 25, 2006

Respectfully submitted,

By

Lisa Swiszc Hazzard

Registration No. 44,368

EDWARDS ANGELL PALMER & DODGE LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 439-4444

Attorneys/Agents For Applicant



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	09/887,493-Conf. #7718	
			Filing Date	June 22, 2001	
			First Named Inventor	Gregor Cevc	
			Art Unit	1654	
			Examiner Name	S. D. Coe	
Sheet	1	of	3	Attorney Docket Number	58069-CON (47126)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA*	US-4,427,670	01-24-1984	Ofuchi, et al.	
	AB*	US-4,814,161	03-21-1989	Jinks, et al.	
	AC*	US-4,333,927	06-08-1982	Ofuchi, et al.	
	AD*	US-6,835,392-B2	12-28-2004	Hsu, et al.	
	AE*	US-6,562,370-B2	05-13-2003	Luo, et al.	
	AF*	US-6,582,724-B2	06-24-2003	Hsu, et al.	
	AG*	US-6,645,520-B2	11-11-2003	Hsu, et al.	
	AH*	US-6,586,000-B2	07-01-2003	Luo, et al.	
	AI*	US-2002/0048596-A1	04-25-2002	Cevc	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO-97/21428	06-19-1997	VESIFACT AG		✓
	BB	WO-95/35095	12-28-1995	YESSUM RESEARCH DEVELOPMENT COMPANY		
	BC	WO-81/02673	10-01-1981	Key Pharmaceuticals, Inc		
	BD	DE-40 26 833.0	08-24-1990		Priority document of BF	
	BE	EP 0 102 324	07-25-1983	CIBA-GEIGY AG		✓
	BF	EP 0 475 160	08-23-1991	G. Cevc		✓
	BG	DE 44 47 287	11-07-1996			✓
	BH	EP-0 995 435	04-26-2000	SENJU PHARMACEUTICAL CO., LTD.		
	BI	EP-0 355 095	08-04-1993	THE LIPOSOME COMPANY, INC.		
	BJ	EP-0 382 716	01-28-1998	WARNER-LAMBERT CO.		
	BK	HU-9903363	03-28-2000		English abstract; corresponds to US 2002/0048596	
	BL	HU-0104424	03-28-2002		English abstract; corresponds to WO 00/38653	
	BM	HU-0105400	05-29-2002		English abstract; corresponds to WO 00/44350	
	BN	WO-00/44350	08-03-2000			
	BO	WO-00/38653	07-06-2000	IDEA INNOVATIVE DERMALE APPLICATIONEN GMBH		
	BP	WO-92/22292	12-23-1992	SCHWARZ PHARMA AG	English abstract	
	BQ	WO-00/25822	05-11-2000	John C. GRASELA, et al.		
	BR	WO-02/11683	02-14-2002	DOW PHARMACEUTICAL SCIENCES		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	09/887,493-Conf. #7718	
			Filing Date	June 22, 2001	
			First Named Inventor	Gregor Cevc	
			Art Unit	1654	
			Examiner Name	S. D. Coe	
Sheet	2	of	3	Attorney Docket Number	58069-CON (47126)

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BS	WO-01/12155	02-22-2001	LIPOCINE, INC.		
	BT	WO-02/07767-A2	01-31-2002	ALCON UNIVERSAL LTD.		
	BU	WO-98/07414	02-26-1998	RESEARCH TRIANGLE PHARMACEUTICALS LTD.		
	BV	WO-00/13684	03-16-2000	LOMA LINDA UNIVERSITY MEDICAL CENTER		
	BW	WO-01/01963	01-11-2001	IDEA AG		
	BQ	WO-96/29999	10-03-1996	HEXAL AG	English abstract	
	BY	WO-94/26257	11-24-1994	LTS LOHMANN THERAPIE-SYSTEME GMBH & CO.	English abstract	
	BZ	WO-00/50007	08-31-2000	LIPOCINE, INC.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
*	CA	Ulmans Encyklopadie der technischen Chemie, Autoren- und Sachregister, pp. 245-246.	✓
*	CB	Prof. Dr. Jurgen Falbe, et al., "Rompp Chemie Lexikon," p.3168.	
*	CC	Encyclopedia of Chemical Technology, Third Edition, pp. 835-836.	
*	CD	Kurt H. Bauer, et al., "Lehrbuch der Pharmazeutischen Technologie," p. 464, 1999.	
*	CE	Dr. Ursula Schoffing, Trier, "Ein Lehrbuch der Galenik Fur Theorie und Praxis," p. 459, 1998.	
*	CF	B. Halliwell and J. M.C. Gutteridge, "Free Radicals in Biology and Medicine," Third Edition, p. 925.	
*	CG	Klare S. Markley, "Fatty Acids: Their Chemistry, Properties, Production, and Uses," Second Completely Revised and Augmented Edition, Part 1, p. 703, 1960.	
*	CH	Klare S. Markley, "Fatty Acids: Their Chemistry, Properties, Production, and Uses," Second Completely Revised and Augmented Edition, Part 2, pp. 1473-1474, 1961.	
*	CI	Dr. Hermann Pardun, "Die Pflanzenlecithine: Gewinnung, Eigenschaften, Verarbeitung und Anwendung pflanzlicher Phosphatidpraparate," Verlag fur chemische Industrie H. Ziolkowsky KG, Augsburg, p. 552, 1988.	
*	CJ	Gregory Gregoriadis, "Drug Carriers in Biology and Medicine," Academic Press, p. 361-361, 1979.	
*	CK	Gregor Cevc, "Phospholipids Handbook," Marcel Dekker, Inc., p. 878, 1993.	
*	CL	"The detection of oxidation in liposome preparations," <i>Biochim. Biophys. Acta</i> , 210, pp. 486-489, 1970.	
*	CM	Dov Lichtenberg, "Liposomes: Preparation, Characterization, and Preservation," <i>Methods of Biochemical Analysis</i> , Vol. 33, pp. 337, 359-360..	

Examiner Signature	Date Considered
--------------------	-----------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/887,493-Conf. #7718
				Filing Date	June 22, 2001
				First Named Inventor	Gregor Cevc
				Art Unit	1654
				Examiner Name	S. D. Coe
Sheet	3	of	3	Attorney Docket Number	58069-CON (47126)

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
*	CN	Dr. Ernst Mutschler, "Arzneimittel-wirkungen: Lehrbuch der pharmakologie und Toxikologie," 1991.	✓	
*	CO	Dr. Rainer H. Muller, et al., "Pharmazeutische Technologie: Moderne Arzneiformen," 1998.	✓	
*	CP	Phospholipids in Cosmetics and Pharmaceuticals, Rhone-Poulenc Rorer, Nattermann Phospolipid GMBH, p. 9/51, April 1997.		
*	CQ	H. Sucker, et al., "Pharmazeutische Technologie," pp. 644-649, 1978.	✓	
*	CR	H. Sucker, et al., "Pharmazeutische Technologie," pp. 288, 293-300, 1978.	✓	
*	CS	H. Sucker, et al., "Pharmazeutische Technologie," pp. 312-315, 1978.	✓	
*	CT	H. Sucker, et al., "Pharmazeutische Technologie," pp. 315-320, 1978.	✓	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--